Merlo, Daniel, Stankovich, Jim, Darby, David, Butzkueven, Helmut, Van der Walt, Anneke, Bai, Claire, Kalincik, Tomas, Zhu, Chao, Gresle, Melissa, Lechner-Scott, Jeannette, Kilpatrick, Trevor, Barnett, Michael, Taylor, Bruce. Wolters Kluwer Health; 2021. Association between cognitive trajectories and disability progression in patients with relapsing-remitting multiple sclerosis.

Binder, Michele D., Fox, Andrew D., Laverick, Louise, Foo, Grace, Fabis-Pedrini, Marzena J., Spelman, Timothy, Jordan, Margaret A., Baxter, Alan G., Foote, Simon, , , , Merlo, Daniel, , , , , , , , , , Lechner-Scott, Jeannette, Johnson, Laura J., , , , , , Moscato, Pablo, Scott, Rodney, , , , Giuffrida, Sarah E., , Calvert, Rainer, Akkermann, Rainer, Ma, Gerry Z. M., Perera, Ashwyn A., Gresle, Melissa M.. Public Library of Science (PLoS); 2016. Common and low frequency variants in MERTK are independently associated with multiple sclerosis susceptibility with discordant association dependent upon HLA-DRB1*15:01 status.

Yam, Charmaine, Merlo, Daniel, Stankovich, Jim, Darby, David, Gresle, Melissa, Kalincik, Tomas, Kilpatrick, Trevor J., Lechner-Scott, Jeanette, Taylor, Bruce, Barnett, Michael, Butzkueven, Helmut, van der Walt, Anneke. Elsevier; 2020. The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis.

Lechner-Scott, Jeannette, Agland, Susan, Allan, Michelle, Darby, David, Diamond, Keri, Merlo, Daniel, van der Walt, Anneke. Elsevier; 2023. Managing cognitive impairment and its impact in multiple sclerosis: An Australian multidisciplinary perspective.

Zhu, Chao, Zhou, Zhen, Alroughani, Raed, Lechner-Scott, Jeannette, Barnett, Michael, Izquierdo, Guillermo, Prat, Alexandre, Horakova, Dana, Havrdova, Eva Kubala, Macdonell, Richard, Patti, Francesco, Khoury, Samia Joseph, Roos, Izanne, Slee, M, Karabudak, R, Onofrj, M, Van Pesch, V, Prevost, J, Monif, M, Jokubaitis, V, van der Walt, A, Butzkueven, H, Merlo, Daniel, Kalincik, Tomas, Ozakbas, Serkan, Skibina, Olga, Kuhle, Jens, Hodgkinson, Suzanne, Boz, Cavit. BMJ Group; 2022. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.